Papers/PMID:34907021
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial.
Clinical journal of the American Society of Nephrology : CJASN2022The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
curcumin — no detected effect on flow-mediated dilation
Evidence strength: very limited.FindingNull result“Neither coprimary end point changed with curcumin (estimated change [95% confidence interval] for brachial artery flow-mediated dilation [percentage change]: curcumin: 1.14; 95% confidence interval, -0.84 to 3.13; placebo: 0.33; 95% confidence interval, -1.34 to 2.00; estimated difference for change: 0.81; 95% confidence interval, -1.21 to 2.84; P=0.48; aortic pulse-wave velocity [centimeters per second]: curcumin: 0.6; 95% confidence interval, -25.7 to 26.9; placebo: 6.5; 95% confidence interval, -20.4 to 33.5; estimated difference for change: -5.9; 95% confidence interval, -35.8 to 24.0; P=0.67; intent to treat).”
Quoted verbatim from Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- 25 mg/kg body weight per day, powder form
- Population
- 68 children and young adults aged 6-25 with ADPKD and eGFR above 80 ml/min per 1.73 m2; coprimary endpoint; intent to treat; 12 months
Effect 0.81 mean difference, 95% CI -1.21 to 2.84
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial.2022PMID:3490702110.2215/CJN.08950621Permalink